Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 2/2016

01-04-2016 | Original Article

Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis

Authors: Sigurdis Haraldsdottir, Rachel Roth, Rachel Pearlman, Heather Hampel, Christina A. Arnold, Wendy L. Frankel

Published in: Familial Cancer | Issue 2/2016

Login to get access

Abstract

Universal screening for mismatch repair deficiency (dMMR) in cancer is increasingly being implemented to detect Lynch syndrome and aid in treatment decisions. The mismatch repair (MMR) immunohistochemistry (IHC) concordance rate between primary colorectal cancer (CRC) and metastasis is unknown. At times, only metastatic tumor is available for screening (lymph node, liver, lung etc.) rather than the primary tumor. Therefore, it is important to confirm that tissue from metastases can be used for screening for dMMR. We tested dMMR primary and metastatic tumor to assess concordance between the two. We identified dMMR CRC resected at Ohio State University from 1999 to 2013 and stained a corresponding metastasis for all four MMR proteins (MLH1, MSH2, MSH6, PMS2) with IHC. A total of 50 primary CRC with dMMR and available regional lymph nodes (LN; 26 cases) or other metastatic tissue (24 cases) were identified. Thirteen cases were explained by MLH1 hypermethylation and 10 cases had Lynch syndrome. Two cases had somatic MMR mutations and the etiology for dMMR was unknown in 25 cases. All cases showed concordance in IHC staining between the primary tumor and corresponding metastatic tissue. In 36 cases, metastatic LN/other site was resected at the same time as the primary tumor. In 14 cases, time lapsed [median 16.5 months; quartile (Q)1 8.0; Q3 25; range 3–69] from the primary resection until metastatic resection. Metastatic tissue can be used to screen for Lynch syndrome and dMMR.
Literature
1.
Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M (1993) Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558–561CrossRefPubMed
2.
Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J (1993) Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 53(21):5100–5103PubMed
3.
Hampel H, Frankel WL, Martin E et al (2005) Screening for the Lynch Syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 352(18):1851–1860CrossRefPubMed
4.
Kane MF, Loda M, Gaida GM et al (1997) Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57:808–811PubMed
5.
Haraldsdottir S, Hampel H, Tomsic J et al (2014) Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 147(6):1308–1316CrossRefPubMedPubMedCentral
6.
Mensenkamp AR, Vogelaar IP, van Zelst-Stams WAG et al (2014) Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 146(3):643–646CrossRefPubMed
7.
Rodríguez-Soler M, Pérez-Carbonell L, Guarinos C et al (2013) Risk of cancer in cases of suspected lynch syndrome without germline mutation. Gastroenterology 144(5):926–932CrossRefPubMed
8.
Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN (2009) EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 11(1):42–65CrossRefPubMedPubMedCentral
9.
Network NCC (2014) NCCN genetic/familial high-risk assessment: colorectal. Version 1.2014. Accessed 30 April 2014
10.
Giardiello FM, Allen JI, Axilbund JE et al (2014) Guidelines on genetic evaluation and management of lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Gastroenterology 147(2):502–526CrossRefPubMed
11.
Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257CrossRefPubMedPubMedCentral
12.
Sargent DJ, Marsoni S, Monges G et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28(20):3219–3226CrossRefPubMedPubMedCentral
13.
Network NCC (2015) NCCN clinical practice guidelines in oncology: thyroid carcinoma. Version 3.2015. Accessed 24 July 2015
14.
Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520CrossRefPubMed
15.
Leach FS, Polyak K, Burrell M et al (1996) Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res 56(2):235–240PubMed
16.
Aaltonen L, Peltomaki P, Leach F et al (1993) Clues to the pathogenesis of familial colorectal cancer. Science 260(5109):812–816CrossRefPubMed
17.
Salahshor S, Koelble K, Rubio C, Lindblom A (2001) Microsatellite Instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Investig J Tech Methods Pathol 81(4):535–541CrossRef
18.
Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J Mol Diagn 10(4):293–300CrossRefPubMedPubMedCentral
19.
Kumarasinghe AP, de Boer B, Bateman AC, Kumarasinghe MP (2010) DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. Pathology 42(5):414–420CrossRefPubMed
20.
Shia J, Stadler Z, Weiser MR et al (2011) Immunohistochemical staining for DNA mismatch repair proteins in intestinal tract carcinoma: how reliable are biopsy samples? Am J Surg Pathol 35(3):447–454CrossRefPubMed
21.
Warrier SK, Trainer AH, Lynch AC et al (2011) Preoperative diagnosis of Lynch syndrome with DNA mismatch repair immunohistochemistry on a diagnostic biopsy. Dis Colon Rectum 54(12):1480–1487CrossRefPubMed
22.
Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7):844–847CrossRefPubMed
23.
Hendriks Y, Franken P, Dierssen JW et al (2003) Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 162:469–477CrossRefPubMedPubMedCentral
24.
25.
Hampel H, Frankel WL, Martin E et al (2008) Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol 26(35):5783–5788CrossRefPubMedPubMedCentral
26.
Herman JG, Umar A, Polyak K et al (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 95(12):6870–6875CrossRefPubMedPubMedCentral
27.
Larsen NB, HeibergEngel PJ, Rasmussen M, Rasmussen LJ (2009) Differential expression of hMLH1 in sporadic human colorectal cancer tumors and distant metastases. APMIS 117(11):839–848CrossRefPubMed
Metadata
Title
Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis
Authors
Sigurdis Haraldsdottir
Rachel Roth
Rachel Pearlman
Heather Hampel
Christina A. Arnold
Wendy L. Frankel
Publication date
01-04-2016
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-015-9856-2

Other articles of this Issue 2/2016

Familial Cancer 2/2016 Go to the issue

Original Article

Migrant breast cancer patients and their participation in genetic counseling: results from a registry-based study

Original Article

The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety

Letter to the Editor

Developing and assessing the utility of a You-Tube based clinical genetics video channel for families affected by inherited tumours

Erratum

Erratum to: Methylation of the miR-126 gene associated with glioma progression

Original Article

Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer

Original Article

Exome sequencing identifies potential novel candidate genes in patients with unexplained colorectal adenomatous polyposis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits